EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Lunai Bioworks Inc (LNAI) fair value: what the stock is really worth

As of Oct 15, 2026: fair value of Lunai Bioworks Inc $0.65, price $0.83, upside -20.8%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

LB Lunai Bioworks Inc logo Thin data Oct 16, 2026

Lunai Bioworks Inc

LNAI · US

Weak valuationQuality is weak on top of the rich price.

Our calculation puts a fair price 21% below what the stock costs today.

Negative equity (buybacks among others)
Mixed vs. peers (2/5)
Fair value $0.6541 · Overvalued (−20.8%)
Quality 22/100
Weak Growth
Negative free cash flow
Narrow moat 0/100
Thin data
⚠ Dilution
Watch Lunai Bioworks Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1,004 $0.8255 Fair Value $0.6541 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 16, 2026.

How to read this chart

60‑month range $0.8255 – $1,004 · fair‑value band $0.5296 – $0.7786 · the $0.8255 price screens above the $0.6541 fair value. Dashed = 300-day average. As of Oct 16, 2026.

Follow Lunai Bioworks in your weekly email

Every Wednesday you see whether Lunai Bioworks is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics.

Show moreShow less

The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.

It also develops BioSymetrics platform, for multi-omics integration for target identification and validation; clinical trial optimization, including patient stratification and response monitoring; and screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics.

The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is based in Sacramento, California.

Stock analysis

Lunai Bioworks Inc (LNAI) currently trades at $0.8255, while our model-based Fair Value estimate is $0.6541, 20.8% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.5296 (bear) to $0.7786 (bull), the price of $0.8255 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Lunai Bioworks Inc reported revenue of $52.0K in FY2026 versus $0 in FY2022. Reported net income was −$3.6B in FY2026.

Key figures

Market cap $3.8M · P/S ratio 77.8 · EPS (TTM) $−53.76 · Return on equity −325% · Return on assets (EBIT) −95.7% · Operating margin −6,889% · Revenue (TTM) $52.0K · Free cash flow −$5.3B.

What moves the price

The share trades about 93% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −21%, LNAI screens richer than that median.

Fair Value models

Bear $0.5296 Fair Value $0.6541 Bull $0.7786
Price $0.8255 · Upside -20.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA $0.6903 $0.7695 $0.8487 64
All 1 models by family
Multiples
EV/EBITDA $0.6903 $0.7695 $0.8487 64

Open the full fair value analysis →

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 22
Do the profits arrive as real cash?
Financial strength 19
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 0
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

LNAI screens overvalued: fair value 21% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Lunai Bioworks Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 603 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −20.8% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −35.8% · Below median
Growth and dividend
Revenue growth 0.0% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 73.28× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)6 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $746.54 $1,275 +71% vs LNAI
Vertex Pharmaceuticals Incorporated VRTX $510.08 $561.09 +10% vs LNAI
argenx SE ARGX $825.03 $907.53 +10% vs LNAI
Samsung Biologics Co 207940 1,219,000 KRW 1,340,900 KRW +10% vs LNAI
WuXi Biologics (Cayman) Inc 2269 HK$52.65 HK$57.92 +10% vs LNAI
CSL Limited CSL A$181.46 A$179.90 −1% vs LNAI
Alnylam Pharmaceuticals, Inc ALNY $232.68 $217.88 −6% vs LNAI
BeOne Medicines AG ONC $354.47 $280.94 −21% vs LNAI
Celltrion, Inc 068270 180,400 KRW 74,519 KRW −59% vs LNAI
Royalty Pharma plc RPRX $56.93 $19.01 −67% vs LNAI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lunai Bioworks Inc · Fair Value
$0.6541 −21%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lunai Bioworks Inc Fair Value". https://www.fairvalue-calculator.com/stock/LNAI

Frequently asked questions

Is Lunai Bioworks Inc (LNAI) overvalued or undervalued?
As of Oct 16, 2026, our model estimates a fair value of $0.6541 versus a price of $0.8255, about −21% upside (overvalued).
What is the fair value of LNAI?
Our model-based fair value for Lunai Bioworks Inc is $0.6541 (as of Oct 16, 2026), built from audited fundamentals. The current price: $0.8255.
What is the quality score of LNAI?
Lunai Bioworks Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lunai Bioworks Inc (LNAI)?
Our model-based price target is the fair value of $0.6541 (as of Oct 16, 2026) from 1 valuation models. Cautious scenario $0.5296, optimistic scenario $0.7786. It is a calculation from audited fundamentals, not an analyst target.
What is the Lunai Bioworks Inc stock forecast for 2026?
Our models put fair value at $0.6541, about −21% upside versus a price of $0.8255 (overvalued). Cautious scenario $0.5296, optimistic scenario $0.7786. The calculation is refreshed regularly with new filings.
What is the revenue of Lunai Bioworks Inc (LNAI)?
Lunai Bioworks Inc reported trailing-twelve-month revenue of about $52.0K (latest available figure, as of Oct 16, 2026).
What is the intrinsic value of Lunai Bioworks Inc (LNAI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lunai Bioworks Inc it is $0.6541 per share (as of Oct 16, 2026), against a price of $0.8255. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Lunai Bioworks Inc stock overvalued or undervalued in 2026?
As of Oct 16, 2026, LNAI trades above its calculated fair value: price $0.8255, fair value $0.6541, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LNAI?
No. The price is what the market pays today ($0.8255); the fair value is what the company's own numbers justify ($0.6541). For Lunai Bioworks Inc the two are $0.1714 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lunai Bioworks Inc worth?
The market values Lunai Bioworks Inc at about $3.8M (market capitalisation, as of Oct 16, 2026). Per share that is $0.8255; our models calculate a fair value of $0.6541 per share.
What do the bullish and bearish scenarios say about LNAI?
Our models span a range for Lunai Bioworks Inc: cautious scenario $0.5296, base $0.6541, optimistic $0.7786 per share (as of Oct 16, 2026, price $0.8255). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lunai Bioworks Inc (LNAI)?
Balance-sheet figures for Lunai Bioworks Inc (as of Oct 16, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is LNAI from its 52-week high?
Lunai Bioworks Inc trades at $0.8255, about 93% below its 52-week high of $12.00 and at the low of $0.8255 (as of Oct 15, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6541 is for.
Which stocks are comparable to Lunai Bioworks Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lunai Bioworks Inc stock attractive at the current price?
The data as of Oct 16, 2026: price $0.8255, calculated fair value $0.6541 (−21%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LNAI calculated?
We run Lunai Bioworks Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6541, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. Lunai Bioworks Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lunai Bioworks Inc (LNAI)?
The closing price on Oct 15, 2026 was $0.8255. Our model-based fair value is $0.6541, about −21% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lunai Bioworks Inc right now?
The price sits above even our optimistic bull case ($0.7786). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Lunai Bioworks Inc

How large is the market capitalisation of Lunai Bioworks Inc (LNAI)?
The market capitalisation of Lunai Bioworks Inc is $3.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lunai Bioworks Inc (LNAI)?
The price-to-sales ratio of Lunai Bioworks Inc is 77.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lunai Bioworks Inc (LNAI)?
Earnings per share at Lunai Bioworks Inc are $−53.76. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Lunai Bioworks Inc (LNAI)?
The return on equity (ROE) of Lunai Bioworks Inc is −325% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lunai Bioworks Inc (LNAI)?
On an EBIT basis the return on assets of Lunai Bioworks Inc is −95.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lunai Bioworks Inc (LNAI)?
The operating margin of Lunai Bioworks Inc is −6,889% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Lunai Bioworks Inc (LNAI) generate?
The free cash flow of Lunai Bioworks Inc is −$5.3B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Lunai Bioworks Inc (LNAI) hold?
Lunai Bioworks Inc holds more cash than debt, $375M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Lunai Bioworks Inc in the live analysis

One click puts Lunai Bioworks Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.